DE602004017962D1 - Neue hemmer der bildung von ages (advanced glycation endproducts) - Google Patents
Neue hemmer der bildung von ages (advanced glycation endproducts)Info
- Publication number
- DE602004017962D1 DE602004017962D1 DE602004017962T DE602004017962T DE602004017962D1 DE 602004017962 D1 DE602004017962 D1 DE 602004017962D1 DE 602004017962 T DE602004017962 T DE 602004017962T DE 602004017962 T DE602004017962 T DE 602004017962T DE 602004017962 D1 DE602004017962 D1 DE 602004017962D1
- Authority
- DE
- Germany
- Prior art keywords
- proteins
- aging
- hemmer
- ages
- education
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010005094 Advanced Glycation End Products Proteins 0.000 title 1
- 230000036252 glycation Effects 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000032683 aging Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000004132 cross linking Methods 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010063493 Premature ageing Diseases 0.000 abstract 1
- 208000032038 Premature aging Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 238000002845 discoloration Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/358,403 US7030133B2 (en) | 1999-04-05 | 2003-02-05 | Inhibitors of formation of advanced glycation endproducts (AGEs) |
PCT/US2004/003203 WO2004071416A2 (en) | 2003-02-05 | 2004-02-05 | Novel inhibitors of formation of advanced glycation endproducts (ages) |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004017962D1 true DE602004017962D1 (de) | 2009-01-08 |
Family
ID=32867908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004017962T Expired - Lifetime DE602004017962D1 (de) | 2003-02-05 | 2004-02-05 | Neue hemmer der bildung von ages (advanced glycation endproducts) |
Country Status (8)
Country | Link |
---|---|
US (1) | US7030133B2 (de) |
EP (1) | EP1594492B1 (de) |
JP (1) | JP2007525418A (de) |
AT (1) | ATE415159T1 (de) |
AU (1) | AU2004211899C1 (de) |
CA (1) | CA2514356C (de) |
DE (1) | DE602004017962D1 (de) |
WO (1) | WO2004071416A2 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030133B2 (en) | 1999-04-05 | 2006-04-18 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGEs) |
EP2269601A1 (de) | 2003-10-27 | 2011-01-05 | City of Hope | LR-9, LR-74 and LR-90 zur Verwendung in der Behandlung von Diabetes-bedingten Komplikationen |
WO2005040102A2 (en) * | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd. | Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them |
WO2007044309A2 (en) * | 2005-10-05 | 2007-04-19 | Vasix Corporation | Device and method for inhibiting age complex formation |
DE102007041232A1 (de) | 2007-08-30 | 2009-03-05 | Henkel Ag & Co. Kgaa | Verwendung von Sulfonylharnstoffen zur Spaltung von AGEs |
DE102007054653A1 (de) | 2007-11-14 | 2009-05-20 | Henkel Ag & Co. Kgaa | Verwendung von Thioharnstoff-Derivaten zur Spaltung von AGEs |
US20120071502A1 (en) * | 2010-09-17 | 2012-03-22 | Cell Viable Corporation | Novel phenoxyisobutyric acid compounds and methods for synthesis |
WO2012103523A2 (en) | 2011-01-27 | 2012-08-02 | Samuel Rahbar | Novel modulators of development of adipocyte and cancer cells |
US9808434B2 (en) | 2011-01-27 | 2017-11-07 | City Of Hope | Compound for treating cancer and diabetes |
JP6306825B2 (ja) * | 2012-11-30 | 2018-04-04 | 上野製薬株式会社 | 終末糖化産物生成抑制剤 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0159287B1 (de) * | 1984-03-15 | 1989-10-11 | Ciba-Geigy Ag | Verwendung von Chinolinderivaten zum Schützen von Kulturpflanzen |
US5272176A (en) * | 1984-03-19 | 1993-12-21 | The Rockefeller University | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
US5100919A (en) | 1984-03-19 | 1992-03-31 | The Rockefeller University | Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein |
DE3410927A1 (de) * | 1984-03-24 | 1985-10-03 | Hoechst Ag, 6230 Frankfurt | Vollaromatische polyester, verfahren zu ihrer herstellung und entsprechende formkoerper |
US5268500A (en) * | 1987-06-15 | 1993-12-07 | Montefiore Medical Center | Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation |
US5093367A (en) * | 1988-06-15 | 1992-03-03 | Montefiore Medical Center | Method of synthesis and novel compounds for pharmaceutical uses |
US4921997A (en) * | 1988-06-15 | 1990-05-01 | Montefiore Medical Center | Method of synthesis and novel compounds for pharmaceutical uses |
US5677330A (en) * | 1990-02-12 | 1997-10-14 | The Center For Innovative Technology | Medical uses of allosteric hemoglobin modifier compounds in patient care |
US6046222A (en) | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
WO1995031192A1 (en) | 1994-05-16 | 1995-11-23 | Thomas Jefferson University | Method and use of agents to inhibit protein polymerization and methods of identifying these agents |
US5661139A (en) * | 1995-01-13 | 1997-08-26 | Alteon Inc. | Bis-(2-aryl) hydrazones |
US5962651A (en) * | 1995-01-27 | 1999-10-05 | Montefiore Medical Center | Modified hemoglobin and its use as a component of an artificial blood substitute |
US5602277A (en) * | 1995-03-30 | 1997-02-11 | Biocryst Pharmaceuticals, Inc. | Substituted benzene derivatives useful as neuraminidase inhibitors |
US5716987A (en) * | 1996-06-21 | 1998-02-10 | Bristol-Myers Squibb Company | Prophylactic and therapeutic treatment of skin sensitization and irritation |
US6589944B1 (en) * | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
US7030133B2 (en) | 1999-04-05 | 2006-04-18 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGEs) |
US6787566B2 (en) * | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
US6605642B2 (en) | 1999-04-05 | 2003-08-12 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGES) |
US6337350B1 (en) * | 1999-04-05 | 2002-01-08 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGEs) |
WO2000066102A2 (en) | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
-
2003
- 2003-02-05 US US10/358,403 patent/US7030133B2/en not_active Expired - Lifetime
-
2004
- 2004-02-05 CA CA2514356A patent/CA2514356C/en not_active Expired - Lifetime
- 2004-02-05 DE DE602004017962T patent/DE602004017962D1/de not_active Expired - Lifetime
- 2004-02-05 JP JP2006503321A patent/JP2007525418A/ja active Pending
- 2004-02-05 EP EP04708575A patent/EP1594492B1/de not_active Expired - Lifetime
- 2004-02-05 AU AU2004211899A patent/AU2004211899C1/en not_active Expired
- 2004-02-05 AT AT04708575T patent/ATE415159T1/de not_active IP Right Cessation
- 2004-02-05 WO PCT/US2004/003203 patent/WO2004071416A2/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
EP1594492A2 (de) | 2005-11-16 |
EP1594492B1 (de) | 2008-11-26 |
EP1594492A4 (de) | 2007-04-18 |
AU2004211899B2 (en) | 2009-09-24 |
JP2007525418A (ja) | 2007-09-06 |
WO2004071416A2 (en) | 2004-08-26 |
WO2004071416B1 (en) | 2004-11-25 |
CA2514356C (en) | 2012-05-08 |
WO2004071416A3 (en) | 2004-10-14 |
AU2004211899A1 (en) | 2004-08-26 |
ATE415159T1 (de) | 2008-12-15 |
US20030220362A1 (en) | 2003-11-27 |
AU2004211899C1 (en) | 2010-05-20 |
CA2514356A1 (en) | 2004-08-26 |
US7030133B2 (en) | 2006-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60219894D1 (de) | Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte | |
DE60008509D1 (de) | Neue hemmern von fortgeschrittenen glykosilierung-endprodukten | |
Tessier | The Maillard reaction in the human body. The main discoveries and factors that affect glycation | |
DE602004017962D1 (de) | Neue hemmer der bildung von ages (advanced glycation endproducts) | |
EA200501132A1 (ru) | 1,2,3-тризамещённые арильные и гетероарильные производные в качестве модуляторов метаболизма и профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия | |
ATE432690T1 (de) | Formel für injizierbares flüssiges paracetamol | |
JP4929181B2 (ja) | アルブミン変性剤 | |
CY1108736T1 (el) | Φαινυλ-και πυριδυλπιπεριδινο-παραγωγα ως ρυθμιστες μεταβολισμου γλυκοζης | |
ATE543798T1 (de) | Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1 | |
EA200600240A1 (ru) | Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением матеболизма | |
DE602007007614D1 (de) | Substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1 | |
DE602005020269D1 (de) | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren | |
ATE408841T1 (de) | Assay zum nachweis von glykiertem oder glykosyliertem hämoglobin (hba1c) | |
EA200601553A1 (ru) | Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды | |
ATE542811T1 (de) | Piperidinylsubstituierte pyrrolidinone als inhibitoren von 11-beta- hydroxysteroiddehydrogenase 1 | |
NO20065122L (no) | 1,1'-(1,2-etyndiyl)bis-benzenderivater som PTP 1-B-hemmere | |
EA200701756A1 (ru) | Соль производного пролина, её сольват и способ её получения | |
DE60331312D1 (de) | Behandlung von einer cellulosehaltigen mischung mit einem reduzierenden mittel | |
EA200800785A1 (ru) | 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором | |
BRPI0409072A (pt) | métodos para seleção e desenvolvimento de um material particulado | |
Bohlooli et al. | Comparative study of thermal domains analyzing of glycated and non-glycated human serum albumin | |
Bala et al. | Interaction of glycated human serum albumin with endothelial cells in a hemodynamic environment: structural and functional correlates | |
ATE439854T1 (de) | Proteinhydrolysat mit antidiabetischer wirkung | |
Ariaeenejad et al. | Biochemical characterization of hemoglobins from Caspian Sea sturgeons (Acipenser persicus and Acipenser stellatus) | |
Peterson et al. | Domain-Specific Effector Interactions within the Central Cavity of Human Adult Hemoglobin in Solution and in Porous Sol− Gel Matrices: Evidence for Long-Range Communication Pathways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |